Patients with advanced-stage cancer seek treatments that prolong survival and improve quality of life. We analysed new anticancer drug indications approved by the FDA and EMA between 2020 and 2023 using the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale quality-of-life checklist. Our findings highlight critical gaps in the availability and reliability of quality-of-life outcomes from the pivotal trials that support these approvals.
This is a preview of subscription content, access via your institution
Access options
/* style specs start */ /* style specs end */
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Purchase on SpringerLink Instant access to full article PDF Buy now
Prices may be subject to local taxes which are calculated during checkout
/* style specs start */ style { display: none !important; } .LiveAreaSection * { align-content: stretch; align-items: stretch; align-self: auto; animation-delay: 0s; animation-direction: normal; animation-duration: 0s; animation-fill-mode: none; animation-iteration-count: 1; animation-name: none; animation-play-state: running; animation-timing-function: ease; azimuth: